Publications by Frontier Pharma

1. Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N: Identification of cell-active lysine specific demethylase 1-selective inhibitors. J. Am. Chem. Soc. 131, 17536–17537 (2009)

2. Ueda J, Kunoh T, Sekigawa M, Wada S, Mukai Y, Ohta S, Sasaki R, Mizukami T, Takagi M, Shin-ya K: JBIR-14, a highly-oxygenated ergostane, from Isaria sp. NBRC 104353. J. Antibiot. 63, 139-141 (2010)

3. Sekigawa M, Kunoh T, Wada S, Mukai Y, Ohta S, Goshima N, Sasaki R, Mizukami T: Comprehensive Screening of Human Genes with Inhibitory Effects on Yeast Growth and Validation of a Yeast Cell-Based System for Screening Chemicals. J Biomol Screen. 15, 368-378 (2010)

4. Hamada S, Suzuki T, Mino K, Koichi Koseki, Oehme F, Flamme I, Ozasa H, Itoh Y, Ogasawara D, Komaarashi H, Kato A, Tsumoto H, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N: Design, Synthesis, Enzyme-inhibitory Activity, and Effect on Human Cancer Cells of a Novel Series of Jumonji Domain-Containing Protein 2 Histone Demethylase Inhibitors. J. Med. Chem. 53, 5629-5638 (2010)

5. Kunoh T, Noda T, Koseki K, Sekigawa M, Takagi M, Shin-ya K, Goshima N, Iemura S, Natsume T, Wada S, Mukai Y, Ohta S, Sasaki R, Mizukami T: A Novel Human Dynactin-Associated Protein, dynAP, Promotes Activation of Akt, and Ergosterol-Related compounds Induce dynAP-Dependent Apoptosis of Human Cancer Cells. Mol Cancer Ther. 9, 2934-2942 (2010)

6. Hasegawa M, Miura T, Kuzuya K, Inoue A, Ki, SW Horinouchi S, Yoshida T, Kunoh T, Koseki K, Mino K, Sasaki R, Yoshida M, Mizukami T: Identification of SAP155 as the Target of GEX1A (Herboxidiene), An Antitumor Natural Product. ACS Chem. Biol. 6, 229-233 (2011)

7. Ogasawara D, Suzuki T, Mino K, Ueda R, Khan MNA, Matsubara T, Koseki K, Hasegawa M, Sasaki R, Nakagawa H, Mizukamic T, Miyata N: Synthesis and biological activity of optically active NCL-1, a lysine specific demethylase 1-selective inhibitor. Bioorg. Med. Chem. 19, 3702–3708 (2011)

8. Ogasawara D, Itoh Y, Tsumoto H, Kakizawa T, Mino K, Fukuhara K, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Miyata N, Suzuki T: Lysine-Specific Demethylase 1-Selective Inactivators: Protein-Targeted Drug Delivery Mechanism. Angew. Chem. Int. Ed. 52, 8620- 8624 (2013)

9. Suzuki T, Ozasa H, Itoh Y, Zhan P, Sawada H, Mino K, Walport L, Ohkubo R, Kawamura A, Yonezawa M, Tsukada Y, Tumber A, Nakagawa H, Hasegawa M, Sasaki R, Mizukami T, Schofield CJ, Miyata N: Identification of the KDM2/7 Histone Lysine Demethylase Subfamily Inhibitor and its Antiproliferative Activity. J. Med. Chem. 56, 7222–7231 (2013)

10. Hasegawa M, Yasuda Y, Tanaka M, Nakata K, Umeda E, Wang Y, Watanabe C, Uetake S, Kunoh T, Shionyu M, Sasaki R, Shiina I, Mizukami T: A novel tamoxifen derivative, ridaifen-F, is a nonpeptidic small-molecule proteasome inhibitor. Eur J Med Chem. 71, 290-305 (2014)

11. Mino K, Nishimura S, Ninomiya S, Tujii H, Matsumori Y, Tsuchida M, Hosoi M, Koseki K, Wada S, Hasegawa M, Sasaki R, Murakami-Yamaguchi Y, Narita H, Suzuki T, Miyata N, Mizukami T: Regulation of Tissue Factor Pathway Inhibitor-2 (TFPI-2) Expression by Lysine-Specific Demethylase 1 and 2 (LSD1 and LSD2) . Biosci Biotechnol Biochem. 7, 1010-1017 (2014)

12. Itoh Y, Sawada H, Suzuki M, Tojo T, Sasaki R, Hasegawa M, Mizukami T, Suzuki T: Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells. ACS Med Chem Lett. 6, 665-670 (2015)

13. Kunoh T, Wang W, Kobayashi H, Matsuzaki D, Togo Y, Tokuyama M, Hosoi M, Koseki K, Wada S, Nagai N, Nakamura T, Nomura S, Hasegawa M, Sasaki R, Mizukami T: Human Dynactin-Associated Protein Transforms NIH3T3 Cells to Generate Highly Vascularized Tumors with Weak Cell-Cell Interaction. PLoS One. e0135836. doi: 10.1371/journal.pone.0135836 (2015)

14. Itoh Y, Aihara K, Mellini P, Tojo T, Ota Y, Tsumoto H, Solomon VR, Zhan P, Suzuki M, Ogasawara D, Shigenaga A, Inokuma T, Nakagawa H, Miyata N, Mizukami T, Otaka A, Suzuki T: Identification of SNAIL1 Peptide-Based Irreversible Lysine Specific Demethylase 1-Selective Inactivators. J Med Chem.  59, 1531-1544 (2016)

15. Kakizawa T, Mizukami T, Itoh Y, Hasegawa M, Sasaki R, Suzuki T: Evaluation of phenylcyclopropylamine compounds by enzymatic assay of lysine-specific demethylase 2 in the presence of NPAC peptide. Bioorg Med Chem Lett. 26, 1193-1195 (2016)

16. Tanaka M, Zhu Y, Shionyu M, Ota N, Shibata N, Watanabe C, Mizusawa A, Sasaki R, Mizukami T, Shiina I, Hasegawa M: Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death. Eur J Med Chem. 146, 636-650 (2018)

17. Mitsui E, Yoshida S, Shinoda Y, Matsumori Y, Tsujii H, Tsuchida M, Wada S, Hasegawa M, Ito A, Mino K, Onuki T, Yoshida M, Sasaki R, Mizukami T: Identification of ryuvidine as a KDM5A inhibitor. Sci Rep. 9952. doi: 10.1038/s41598-019-46346-x (2019)

18. Yin X, Yamada S, Kobayashi H, Tanaka R, Togo Y, Hosoi M, Tsuchida M, Kunoh T, Wada S, Nakamura T, Sasaki R, Mizukami T, Hasegawa M: Expression and cell transformation activity of dynactin-associated protein isoforms. FEBS Open Bio. 11, 2110–2117 (2021)

19. Yin X, Konishi T, Horikawa K, Tanaka R, Togo Y, Noda T, Hosoi M, Tsuchida M, Kunoh T, Wada S, Nakamura T, Tsuda E, Sasaki R, Mizukami T, Hasegawa M: Structure and function of potential glycosylation sites of dynactin-associated protein dynAP. Mol Biotechnol. doi: 10.1007/s12033-021-00435-3 (2022)